Case studies

PHM Technology used an R&D facility to take control of their cash flow and keep it healthy now and into the future.

EncompaaS's multi-drawdown strategy with a Kashcade R&D facility unlocked fast capital without any equity dilution.

Identitii used a Kashcade R&D facility to plan ahead of growth and access the capital they needed to scale fast.

Great Wrap secured the necessary funds to continue prioritising material development using a Kashcade R&D advance.

6pillars.ai used a Kashcade R&D advance to unlock their R&D refund so they could maximise their reinvestment into their technology.

Sherlok were in the middle of an equity capital raise and wanted to extend their runway to ensure they had plenty of time to secure the right investors and the right terms.

Kashcade advancing their R&D refund, around 9 months earlier than it would have been paid out, Northmark were able to expedite development of the project.

ResusRight's R&D loan allowed them to access the capital they needed immediately, ensuring their operations could continue without interruption.

Arc Ento Tech's R&D advance enabled them to maintain momentum in their plant development and continue advancing their waste processing technology.

Kashcade’s R&D loan allowed LB Agtech to unlock capital earlier, which was crucial for keeping their development on track.

VGI Health Technology accessed their R&D refund nearly a year ahead of schedule, allowing them to secure the capital they needed immediately.

Plant Based Co were raising equity capital but didn’t want to dilute shareholders more than necessary. A Kashcade R&D loan solved it.

Mad Paws already had equity capital, so instead used an R&D advance alongside it to give them optionality.

Mogoplus bolstered their cash balance even further while in a position of strength, to avoid diluting existing shareholders more than necessary.

Goanna used an R&D advance to ensure cashflows remained smooth and there was no disruption to the customer experience through the busiest time of year.

With equity markets tougher than they had been, Apxium used an R&D advance to avoid giving away more equity than needed to fund growth.